Company: DMAAR
Filing Date: 2025-01-30
Form Type: 8-K
Source: 0001213900-25-008377
Chunk: 1

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-30
Form: 8-K
Item: Item 1.01
Chunk 1
---
 as of January 7, 2025, by and between the Company and Drugs Made In America Acquisition LLC.  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

On January
29, 2025, the Company consummated the IPO of 20,000,000 units (the “ Units”). Each Unit consists of one ordinary share, $0.0001
par value (“ Ordinary Share”) and one right to receive one-eighth (1/8) of one Ordinary Share upon the consummation of an initial
business combination. The Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $200,000,000. The underwriters were granted a 45-day option to purchase up to an additional 3,000,000 Units to cover over-allotments,
if any.

As of January 29, 2025,
a total of $201,000,000 of the net proceeds from the IPO and the Private Placement (as defined below) were deposited in a trust account
established for the benefit of the Company’s public shareholders. An audited balance sheet as of January 29, 2025 reflecting receipt
of the proceeds upon consummation of the IPO and the Private Placement will be filed within four (4) business days of the consummation
of the IPO.

Item 3.02. Unregistered
Sales of Equity Securities.